(CercleFinance.com) – Telix Pharmaceuticals Limited yesterday announced a collaborative development and resale agreement with GE Healthcare for an initial term of 5 years to supply experimental Positron Emission Tomography (PET) imaging radiotracers , TLX250-CDx (89Zr-DFO-girentuximab), and [18F]-FLac (18F-3-fluoro-2-hydroxypropionate) for use in third party clinical R&D activities.
PET scans are a method of medical imaging that can provide key information on the metabolic environment of tumors, which could help inform and improve the choice of therapy.
The TLX250-CDx and the [18F]-FLac will complement GE Healthcare Pharmaceutical Diagnostics’ non-invasive investigational imaging tracer portfolio.
“Ultimately, these PET imaging diagnostics could help deliver effective oncology therapies to patients,” says Sanka Thiru, Global Business Leader, Immuno-Oncology, in GE Healthcare’s Pharmaceutical Diagnostics business.
Under the agreement, GE Healthcare will be responsible for the marketing and sales of Telix’s imaging agents to pharmaceutical companies, with close support from Telix, while Telix will be responsible for the manufacturing and ongoing development of each product.
Copyright © 2022 CercleFinance.com. All rights reserved.
Did you like this article ? Share it with your friends with the buttons below.
